Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PERIPHERAL-BLOOD STEM-CELL CD34+ AUTOLOGOUS TRANSPLANT IN RELAPSED FOLLICULAR LYMPHOMA
Autore:
MARIN GH; DALCORTIVO L; CAYUELA JM; MAROLLEAU JP; PAUTIER P; COJEANZELEK I; BRICE P; MAKKE J; BENBUNAN M; GISSELBRECHT C;
Indirizzi:
HOP ST LOUIS,SERV REANIMAT HEMATOL ADULTE,1 AVE CLAUDE VELLERAUX F-75475 PARIS 10 FRANCE HOP ST LOUIS,SERV REANIMAT HEMATOL ADULTE F-75475 PARIS 10 FRANCE HOP ST LOUIS,CTR SECTEUR HEMOBIOL TRANSFUS SANGUINE F-75475 PARIS 10 FRANCE HOP ST LOUIS,CENT HEMATOL LAB F-75475 PARIS 10 FRANCE HOP ST LOUIS,HOP JOUR HEMATOL F-75475 PARIS 10 FRANCE INST GUSTAVE ROUSSY F-94805 VILLEJUIF FRANCE
Titolo Testata:
HEMATOLOGY AND CELL THERAPY
fascicolo: 1, volume: 39, anno: 1997,
pagine: 33 - 40
SICI:
1269-3286(1997)39:1<33:PSCATI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; AVIDIN-BIOTIN IMMUNOADSORPTION; POLYMERASE CHAIN-REACTION; HIGH-DOSE THERAPY; CONSOLIDATION THERAPY; MYELOABLATIVE THERAPY; BREAST-CANCER; ENGRAFTMENT; PROGENITORS;
Keywords:
FOLLICULAR LYMPHOMA; CD34 SELECTION; PERIPHERAL BLOOD STEM CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
G.H. Marin et al., "PERIPHERAL-BLOOD STEM-CELL CD34+ AUTOLOGOUS TRANSPLANT IN RELAPSED FOLLICULAR LYMPHOMA", HEM CELL TH, 39(1), 1997, pp. 33-40

Abstract

To evaluate CD34+ selection of peripheral blood stem cells (PBSC) as a graft for autologous transplantation. Eight relapsing follicular lymphoma (FL) patients were submitted to CD34+ autologous stem cell transplantation (ASCT). All patients received at least two front line conventional therapies; mean time to treatment failure (TTF) was 4.5 months. Patients had disseminated stage III-IV disease after a median numberof 2.1 relapses. Chemotherapy and G-CSF were used as mobilization forleukapheresis. CEPRATE SC concentrator (CellPro, Inc, Bothell, WA) was used to select CD34+ cells from leukapheresis products. With a mean of 1.8 leukaphereses per patient, 8.1 x 10(8) mononuclear cells (MNCs)/kg were collected. After the selection process, the median number of MNCs was 9.4 x 10(6)/kg; 4.3 x 10(6)/kg CD34+ cells and 17 x 10(4)/kg CFU-GM, with a purity of 83.7% and a viability of 89.2%. Mbr bcl2/IgH PCR analysis of 5 grafts showed that initial buffy-coat, and CD34- fractions were negative in 3 cases and positive in 2 cases (from whom selected CD34+ fraction remained positive in 1 case). After a conditioning regimen including total body irradiation, cyclophosphamide and etoposide, CD34+ selected cells were reinfused. All patients but one had successful engraftment, median time to WBC > 1 x 10(9)/l was 12 days andplatelets > 50 x 10(9)/l 17 days. No severe infectious complications were seen. After transplant, with a minimum follow up of 2 years, 5 patients are still in complete remission (CR). Three patients have relapsed after 1 year of transplant with a mean TTF of 15.6 months. We conclude that PBSC CD34+ selection for ASCT was a safe technique, capable of reconstituting hemopoiesis without severe complications for high risk FL patients included in this study. The effects of tumor cell purging need to be evaluated in a larger series.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 12:59:18